Business Wire: Antiplatelet Market Analysis Report 2024, Featuring Profiles of AstraZeneca, Sanofi, Daiichi Sankyo, Bayer, Torrent Pharmaceuticals, Lupin, Cipla, Baxter, Takeda and Glenmark ...
DUBLIN--(BUSINESS WIRE)--The "Antiplatelet Market: Analysis By Drug Class, By Route of Administration, By Distribution Channel, By Region Size and Trends" report has been added to ...
Antiplatelet Market Analysis Report 2024, Featuring Profiles of AstraZeneca, Sanofi, Daiichi Sankyo, Bayer, Torrent Pharmaceuticals, Lupin, Cipla, Baxter, Takeda and Glenmark ...
MarketWatch: PlateletDiagnostics Announces Novel Immune-Based Platelet Function Assay to Monitor Antiplatelet Therapy
Current guidelines recommend dual antiplatelet therapy, a combination of aspirin and a P2Y 12 inhibitor, for 6–12 months after percutaneous coronary intervention with drug-eluting stent implantation ...
The American Journal of Managed Care: Ticagrelor Antidote Bentracimab Safely Reverses Antiplatelet Effects in Phase 3 REVERSE-IT Trial
Bentracimab effectively reversed ticagrelor's antiplatelet effects, restoring platelet function in minutes for most patients in urgent situations. The REVERSE-IT trial showed 94.3% of patients ...
Ticagrelor Antidote Bentracimab Safely Reverses Antiplatelet Effects in Phase 3 REVERSE-IT Trial
With the aging of the population, use of nonsteroidal anti-inflammatory drugs for musculoskeletal discomfort and other indications has risen. The guideline’s overarching message is that patients who ...
Patients who received a single antiplatelet drug therapy— usually aspirin — after transcatheter aortic valve replacement (TAVR) had about half the risk of dying in the subsequent 6 months compared ...
Abelacimab, an FXI inhibitor, significantly reduces bleeding risks in patients on antiplatelet therapy compared with rivaroxaban. The AZALEA-TIMI 71 study demonstrated consistent bleeding reduction ...